5 June 2009 - Hemocue has signed an agreement with MEC Dynamics for the exclusive distribution of the Avie A1c point-of-care test in the US and Europe.
The test will provide physicians with a Hemoglobin A1c (HbA1c) result in about 3mins, helping them to provide direct patient feedback and make informed decisions at the point of care regarding their patient's diabetes treatment plan.
The terms of the agreement were not disclosed.
With the addition of the Avie A1c test, Hemocue will be able to offer a more complete suite of point-of-care tests for efficient diabetes management.
Physicians can test for and diagnose the disease using the Hemocue Glucose 201 systems.
They monitor for diabetes-related complications with the Hemocue Albumin 201 test for microalbuminuria, a kidney and cardiovascular disease risk marker.
The Avie A1c helps physicians track a diabetic patient's glycemic control over the prior six- to 12 -week period.
The test requires no sample preparation or patient fasting, can be performed using capillary or venous specimen, and provides a percentage as well as the calculated average glucose concentration.
The instrument can be connected to an ancillary printer, and can be supported by customisable data management software.
